Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

News Conference News TCT 2024

Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI

Michael O'Riordan

November 06, 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

News Conference News TCT 2024

EVOLVED: Early AVR Fails to Help Asymptomatic AS Patients With Fibrosis

Michael O'Riordan

October 28, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Valve Fracture for ViV TAVI Linked With Higher Mortality

News Conference News TCT 2022

Valve Fracture for ViV TAVI Linked With Higher Mortality

Michael O'Riordan

September 22, 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

Fracture Improves Gradients in ViV TAVI, but Ideal Timing Still Unknown

News Conference News TCT 2021

Fracture Improves Gradients in ViV TAVI, but Ideal Timing Still Unknown

Michael O'Riordan

October 07, 2021

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

News Conference News TCT 2020

Acurate Neo Still Falls Short of Sapien 3 in SCOPE 1-Year Follow-up

Michael O'Riordan

October 23, 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

News Conference News TCT 2020

Acurate Neo Fails to Match Results of CoreValve Evolut: SCOPE 2

Michael O'Riordan

October 15, 2020

Predicting Final Valve Position After TAVR: Different Devices, Different Success

News Conference News TCT 2019

Predicting Final Valve Position After TAVR: Different Devices, Different Success

Michael O'Riordan

October 07, 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

News Conference News TCT 2019

Personalized CT-Derived Modeling Guides Choices in Bicuspid Aortic Valve Disease

Michael O'Riordan

September 25, 2019

High Mortality but Durable Results With Valve-in-Valve TAVR

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.